Novel formulation for cost-effective and thermo-stable Insulin
Diabetes management has seen a big advance with the introduction of injectable insulin formulations. Insulin, on the other hand, must be kept cold to avoid fibrillation (a form of'solidification,' which renders it unusable after a few hours). Even in a standard refrigerator, storing it for an extended period of time is not recommended. Consequently, its high cost is due to its high thermal instability and fibrillation at non-refrigerated temperatures. Furthermore, the problem is exacerbated for diabetics who are staying in isolated regions without access to a refrigerator or who are on extended trips.
A lot of work is being done around the world to develop thermostable, nontoxic, and bioactive insulin formulations. This study by researchers from the Bose Institute, the CSIR-Indian Institute of Chemical Biology, and the CSIR Indian Institute of Chemical Technology (CSIR-IICT) in Kolkata and Hyderabad has demonstrated that a "Insulock" small peptide molecule made up of four amino acids inhibits insulin fibrillation caused by heat and storage, preventing the loss of insulin's usefulness in diabetics. These researchers discovered that the "Insulock" was safe to use, didn't cause any immune system problems and was heat-stable, meaning it could keep insulin in its active state for months even at room temperature. Researchers have put the "Insulock" to the test on mice. The results of this study have been published in iScience, a prestigious publication from Cell press with an international reputation.
A small peptide identified by Dr. Subhrangsu Chatterje and Dr. Partha Chakrabarti, both of the Bose Institute, has been found to inhibit insulin fibrillation. The second contribution involves the use of high-resolution Nuclear Magnetic Resonance (NMR) Spectroscopy to determine the three-dimensional (3D) structure of the Insulock-insulin complex and its thermal stability. The "Insulock" and its 3D-structural resemblance to the original insulin injection are essential procedures that have been carried out at CSIR-NMR IICT's centre, stated Dr. Jagadeesh of CSIR-IICT," It is the finest place to conduct regulatory studies on medication compounds because this NMR-center has world-class facilities with USFDA-audited and national accreditations.
This research team from Kolkota and Hyderabad believes that the unique Insulock formulation will provide a wealth of opportunities for generating cost-effective insulin injections, especially in resource-limited places. The team also intends to collaborate with Indian pharmaceutical businesses on human trial development, which would be undertaken by them. Pharma corporations with a stake in thermo-stale Insulin production are anticipated to take notice of this revelation.